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Cognitive function, cerebral 
microbleeds, radiotherapy, 
and bevacizumab in 
survivors of pediatric 
brain tumors
We read with great interest a recent paper published by Roddy 
et al showing a high (48.8%) 5-year cumulative incidence of cer-
ebral microbleeds (CMB) and its association with cognitive dys-
function in a group with pediatric brain tumors who received 
cranial radiation therapy (CRT).1 We believe that exposing the 
association of CMB (or the associated underlying microvascu-
lar pathology) with cognitive impairment in this population will 
help draw attention to the importance of the topic in this spe-
cific growing population. In a retrospective cohort study from 
our institution with 132 pediatric brain tumor patients designed 
to address the correlation between CRT focus/dosage with the 
topographic location of CMB using the Microbleed Anatomical 
Rating Scale, we also found CMB in a high percentage (41.5%) 
of patients (unpublished manuscript, Passos et al). It is worth-
while to highlight that operational CMB definition, assessment 
methodology, and follow-up duration all affect CMB preva-
lence.2 In the study by Roddy et al, a small number of patients 
(n = 7) treated with bevacizumab had an increased incidence 
of CMB. Bevacizumab was most probably used in specific 
tumors (high-grade gliomas) or circumstances (medulloblas-
toma recurrence) which could be per se more prone to CMB 
after CRT.3,4 The dynamic nature of radiation-induced microvas-
culopathy must also be taken into account. We have already 
shown that these lesions can progress from CMB to caverno-
mas (Fig. 1, illustrative case), and there are anecdotal cases of 
incidental regression of CRT-induced cavernomas after beva-
cizumab treatment.5 It would be of interest to replicate these 
findings and to compare the frequency of CMB and caverno-
mas in post-CRT survivors of pediatric brain tumors treated 
and not treated with bevacizumab. Disentangling this puzzle 
can possibly help to find strategies to modify the natural his-
tory of chronic microvascular complications after CRT.
Letters to the Editor
Fig. 1 Follow-up brain MRI with gradient recalled echo (GRE)/ T2* sequence of a 27-year-old survivor of childhood primary brain tumor, showing evolu-
tion of a radiation-induced microbleed (1A–C) to a cavernoma (1D–F) in 20 months. Classification according to the current definitions.6,7
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Response to “Cognitive 
function, cerebral 
microbleeds, radiotherapy, 
and bevacizumab in 
survivors of paediatric 
brain tumors”
We thank the authors for their reply to our article. We agree 
that it is of utmost importance to disentangle the complex 
determinants of microvasculopathy development as well 
as the determinants of potential regression in this vulner-
able population of pediatric brain tumor patients. We find 
that their demonstration that radiation-induced cerebral 
microbleeds (CMBs) can progress to cavernomas to be an 
important observation. Although this was not a specific end 
point of our study, we did note that one patient in our cohort 
had a CMB that developed into a cavernous malformation. 
We have previously reported that cavernous malforma-
tions are common in survivors of pediatric brain tumors 
who received radiation and can present on a spectrum of 
histological features.1 It is our goal to continue to follow this 
cohort of patients to observe the natural history of these 
lesions.
Regarding the use of bevacizumab, we acknowledge 
that the population who received this drug may have been 
unique. However, there was no significant difference in 
tumor type or rate of tumor recurrence between patients 
who developed CMBs and those who did not (Table  1).2 
Post-hoc analysis of patients who received bevacizumab 
demonstrates that the rate of recurrence between patients 
who received bevacizumab and those who did not was 
not statistically different (36% and 20%, P = .145), though 
patients with high- or low-grade gliomas were more likely 
to receive bevacizumab (67% versus less than 10% for all 
other tumor types, P  =  .004). Interestingly, others have 
shown that administration of the anti-angiogenic drug 
enzastaurin with cranial radiation therapy was associated 
with decreased rate of additional CMB formation in adults. 
The underlying etiology for this was hypothesized to be a 
potential radioprotective effect of the anti-angiogenic ther-
apy on microvasculature by decreasing capillary perme-
ability and cytokine release.3
Determining the role specifically of bevacizumab on 
CMB development was not the focus of our study, and 
given that we had only 14 patients who received beva-
cizumab, more numbers are needed to further study the 
effect of bevacizumab on CMB development and potential 
evolution.
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